Rentschler: Stabilisation tech sparks 'paradigm shift' for bio-formulation services

By Dan Stanton contact

- Last updated on GMT

Image: iStock/koo_mikko
Image: iStock/koo_mikko
Rentschler Biotechnologie has added an antibody stabilising platform to its manufacturing services through a strategic alliance with formulation tech firm Leukocare.

The deal – financials of which have not been disclosed – sees the contract development and manufacturing organisation (CDMO) take a 10% share in fellow Gemany-based firm Leukocare, while adding what Rentschler spokeswoman Marion Schrader said was “a best-in-class formulation”​ technology.

“Rentschler will become the first and only CDMO to have access to Leukocare´s patented SPS formulation technologies,”​ she told

The SPS – or Stabilizing and Protecting Solutions – technology platform has the ability to stabilise and protect biopharmaceuticals, including therapeutic antibodies, she said.

“SPS are specific compositions of usually 5-8 different selected and regulatory well known excipients out of a library of up to 100 different ones. The formulations offer high stability of proteins in lyophilised or liquid formulations, preventing aggregation and oxidation etc. while fully preserving the functionality of the respective target protein.”

The platform is desirable from Rentschler’s point of view as there is a need to ensure that the end products of our clients will, from the very beginning, have a best-in-class formulation.”

Schrader continued, adding the alliance “is about to initiate a paradigm shift”​ by introducing a full-service concept approach in the development of biopharmaceuticals.

“The SPS formulation technology platform provides this best-in-class stability and allows the development of pharmaceutical formulations in a shorter period of time. This results in a much higher probability of success to develop pharmaceutical formulations meeting defined objectives.”

The platform will be operated from Leukocare’s site in Martinsried, near Munich, with the firm doing the formulation development as requested by Rentschler´s clients.

This is the latest investment by Rentschler which has pursued and completed a series of facility expansions over the past few years​. The latest saw it add a second 2,000L single-use bioreactor​ at its plant in Laupheim.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us


View more